nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—SLC15A1—Lisinopril—dilated cardiomyopathy	0.601	1	CbGbCtD
L-DOPA—Pemphigus—Lisinopril—dilated cardiomyopathy	0.0121	0.0487	CcSEcCtD
L-DOPA—Common cold—Lisinopril—dilated cardiomyopathy	0.00892	0.0358	CcSEcCtD
L-DOPA—Shoulder pain—Lisinopril—dilated cardiomyopathy	0.00865	0.0347	CcSEcCtD
L-DOPA—Leg pain—Lisinopril—dilated cardiomyopathy	0.00504	0.0202	CcSEcCtD
L-DOPA—Blister—Furosemide—dilated cardiomyopathy	0.00431	0.0173	CcSEcCtD
L-DOPA—Ataxia—Spironolactone—dilated cardiomyopathy	0.00389	0.0156	CcSEcCtD
L-DOPA—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00379	0.0152	CcSEcCtD
L-DOPA—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00373	0.015	CcSEcCtD
L-DOPA—Gastritis—Spironolactone—dilated cardiomyopathy	0.00366	0.0147	CcSEcCtD
L-DOPA—Heartburn—Lisinopril—dilated cardiomyopathy	0.00338	0.0136	CcSEcCtD
L-DOPA—PSIP1—cardiac ventricle—dilated cardiomyopathy	0.00304	0.238	CbGeAlD
L-DOPA—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00298	0.0119	CcSEcCtD
L-DOPA—Memory impairment—Lisinopril—dilated cardiomyopathy	0.00297	0.0119	CcSEcCtD
L-DOPA—PSIP1—myocardium—dilated cardiomyopathy	0.00286	0.224	CbGeAlD
L-DOPA—Alopecia—Spironolactone—dilated cardiomyopathy	0.00253	0.0102	CcSEcCtD
L-DOPA—Vascular purpura—Furosemide—dilated cardiomyopathy	0.00252	0.0101	CcSEcCtD
L-DOPA—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.0025	0.01	CcSEcCtD
L-DOPA—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.0024	0.00962	CcSEcCtD
L-DOPA—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00236	0.00946	CcSEcCtD
L-DOPA—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00236	0.00945	CcSEcCtD
L-DOPA—Purpura—Furosemide—dilated cardiomyopathy	0.00234	0.00938	CcSEcCtD
L-DOPA—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00231	0.00928	CcSEcCtD
L-DOPA—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.00226	0.00907	CcSEcCtD
L-DOPA—Malaise—Spironolactone—dilated cardiomyopathy	0.00225	0.00902	CcSEcCtD
L-DOPA—Isoetarine—ADRB1—dilated cardiomyopathy	0.00223	0.141	CrCbGaD
L-DOPA—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00223	0.00895	CcSEcCtD
L-DOPA—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.0022	0.00882	CcSEcCtD
L-DOPA—Urinary retention—Furosemide—dilated cardiomyopathy	0.00214	0.00859	CcSEcCtD
L-DOPA—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00211	0.00847	CcSEcCtD
L-DOPA—Discomfort—Spironolactone—dilated cardiomyopathy	0.0021	0.00841	CcSEcCtD
L-DOPA—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00206	0.00825	CcSEcCtD
L-DOPA—Confusional state—Spironolactone—dilated cardiomyopathy	0.00205	0.00823	CcSEcCtD
L-DOPA—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00203	0.00814	CcSEcCtD
L-DOPA—PSIP1—heart—dilated cardiomyopathy	0.00199	0.156	CbGeAlD
L-DOPA—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00199	0.00799	CcSEcCtD
L-DOPA—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00195	0.00783	CcSEcCtD
L-DOPA—Isoetarine—ADRB2—dilated cardiomyopathy	0.00188	0.119	CrCbGaD
L-DOPA—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.00187	0.00751	CcSEcCtD
L-DOPA—Somnolence—Spironolactone—dilated cardiomyopathy	0.00181	0.00726	CcSEcCtD
L-DOPA—Pollakiuria—Furosemide—dilated cardiomyopathy	0.0018	0.00722	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00176	0.00705	CcSEcCtD
L-DOPA—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00169	0.00678	CcSEcCtD
L-DOPA—Diplopia—Lisinopril—dilated cardiomyopathy	0.00169	0.00678	CcSEcCtD
L-DOPA—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00168	0.00673	CcSEcCtD
L-DOPA—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00168	0.00673	CcSEcCtD
L-DOPA—DRD4—heart—dilated cardiomyopathy	0.00166	0.13	CbGeAlD
L-DOPA—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00162	0.0065	CcSEcCtD
L-DOPA—Urticaria—Spironolactone—dilated cardiomyopathy	0.00162	0.00649	CcSEcCtD
L-DOPA—Ataxia—Lisinopril—dilated cardiomyopathy	0.00159	0.00638	CcSEcCtD
L-DOPA—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00158	0.00635	CcSEcCtD
L-DOPA—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00154	0.00619	CcSEcCtD
L-DOPA—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00154	0.00617	CcSEcCtD
L-DOPA—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00153	0.00613	CcSEcCtD
L-DOPA—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00152	0.00611	CcSEcCtD
L-DOPA—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00151	0.00606	CcSEcCtD
L-DOPA—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.0015	0.00601	CcSEcCtD
L-DOPA—Gastritis—Lisinopril—dilated cardiomyopathy	0.0015	0.006	CcSEcCtD
L-DOPA—Pruritus—Spironolactone—dilated cardiomyopathy	0.00144	0.00578	CcSEcCtD
L-DOPA—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00142	0.00571	CcSEcCtD
L-DOPA—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00142	0.00571	CcSEcCtD
L-DOPA—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00139	0.00559	CcSEcCtD
L-DOPA—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00139	0.00558	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00136	0.00545	CcSEcCtD
L-DOPA—Dizziness—Spironolactone—dilated cardiomyopathy	0.00135	0.0054	CcSEcCtD
L-DOPA—Flatulence—Furosemide—dilated cardiomyopathy	0.00134	0.00536	CcSEcCtD
L-DOPA—Weight increased—Lisinopril—dilated cardiomyopathy	0.00133	0.00533	CcSEcCtD
L-DOPA—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00133	0.00533	CcSEcCtD
L-DOPA—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00132	0.0053	CcSEcCtD
L-DOPA—SLC7A8—heart—dilated cardiomyopathy	0.00131	0.103	CbGeAlD
L-DOPA—Muscle spasms—Furosemide—dilated cardiomyopathy	0.0013	0.00523	CcSEcCtD
L-DOPA—Depression—Lisinopril—dilated cardiomyopathy	0.0013	0.00521	CcSEcCtD
L-DOPA—Vomiting—Spironolactone—dilated cardiomyopathy	0.00129	0.00519	CcSEcCtD
L-DOPA—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00128	0.00515	CcSEcCtD
L-DOPA—Rash—Spironolactone—dilated cardiomyopathy	0.00128	0.00515	CcSEcCtD
L-DOPA—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00128	0.00514	CcSEcCtD
L-DOPA—Vision blurred—Furosemide—dilated cardiomyopathy	0.00128	0.00513	CcSEcCtD
L-DOPA—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00128	0.00512	CcSEcCtD
L-DOPA—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00128	0.00512	CcSEcCtD
L-DOPA—Headache—Spironolactone—dilated cardiomyopathy	0.00127	0.00511	CcSEcCtD
L-DOPA—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00127	0.00508	CcSEcCtD
L-DOPA—Anaemia—Furosemide—dilated cardiomyopathy	0.00125	0.00503	CcSEcCtD
L-DOPA—Agitation—Furosemide—dilated cardiomyopathy	0.00125	0.005	CcSEcCtD
L-DOPA—Norepinephrine—SLC22A5—dilated cardiomyopathy	0.00124	0.0788	CrCbGaD
L-DOPA—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00122	0.00488	CcSEcCtD
L-DOPA—Leukopenia—Furosemide—dilated cardiomyopathy	0.00121	0.00487	CcSEcCtD
L-DOPA—Nausea—Spironolactone—dilated cardiomyopathy	0.00121	0.00485	CcSEcCtD
L-DOPA—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00117	0.0047	CcSEcCtD
L-DOPA—Hallucination—Lisinopril—dilated cardiomyopathy	0.00116	0.00467	CcSEcCtD
L-DOPA—Dopamine—SLC22A5—dilated cardiomyopathy	0.00116	0.0732	CrCbGaD
L-DOPA—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00115	0.00463	CcSEcCtD
L-DOPA—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00115	0.0046	CcSEcCtD
L-DOPA—Dry mouth—Furosemide—dilated cardiomyopathy	0.00113	0.00453	CcSEcCtD
L-DOPA—Epinephrine—SLC22A5—dilated cardiomyopathy	0.00113	0.0715	CrCbGaD
L-DOPA—Confusional state—Furosemide—dilated cardiomyopathy	0.00112	0.00448	CcSEcCtD
L-DOPA—Shock—Furosemide—dilated cardiomyopathy	0.00109	0.00437	CcSEcCtD
L-DOPA—Flushing—Lisinopril—dilated cardiomyopathy	0.00109	0.00435	CcSEcCtD
L-DOPA—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00108	0.00435	CcSEcCtD
L-DOPA—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00107	0.00429	CcSEcCtD
L-DOPA—Anorexia—Furosemide—dilated cardiomyopathy	0.00106	0.00423	CcSEcCtD
L-DOPA—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00104	0.00419	CcSEcCtD
L-DOPA—Hypotension—Furosemide—dilated cardiomyopathy	0.00103	0.00415	CcSEcCtD
L-DOPA—Alopecia—Lisinopril—dilated cardiomyopathy	0.00103	0.00415	CcSEcCtD
L-DOPA—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00102	0.00411	CcSEcCtD
L-DOPA—Droxidopa—ADRB1—dilated cardiomyopathy	0.00102	0.0646	CrCbGaD
L-DOPA—SLC7A5—heart—dilated cardiomyopathy	0.00102	0.0798	CbGeAlD
L-DOPA—Flatulence—Lisinopril—dilated cardiomyopathy	0.001	0.00402	CcSEcCtD
L-DOPA—Tension—Lisinopril—dilated cardiomyopathy	0.000999	0.00401	CcSEcCtD
L-DOPA—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000997	0.004	CcSEcCtD
L-DOPA—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000994	0.00399	CcSEcCtD
L-DOPA—Nervousness—Lisinopril—dilated cardiomyopathy	0.000989	0.00397	CcSEcCtD
L-DOPA—Back pain—Lisinopril—dilated cardiomyopathy	0.000985	0.00395	CcSEcCtD
L-DOPA—Somnolence—Furosemide—dilated cardiomyopathy	0.000984	0.00395	CcSEcCtD
L-DOPA—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000979	0.00393	CcSEcCtD
L-DOPA—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000963	0.00386	CcSEcCtD
L-DOPA—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000959	0.00385	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000956	0.00383	CcSEcCtD
L-DOPA—Fatigue—Furosemide—dilated cardiomyopathy	0.000955	0.00383	CcSEcCtD
L-DOPA—Tremor—Lisinopril—dilated cardiomyopathy	0.000954	0.00383	CcSEcCtD
L-DOPA—Pain—Furosemide—dilated cardiomyopathy	0.000947	0.0038	CcSEcCtD
L-DOPA—Constipation—Furosemide—dilated cardiomyopathy	0.000947	0.0038	CcSEcCtD
L-DOPA—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000944	0.00379	CcSEcCtD
L-DOPA—Anaemia—Lisinopril—dilated cardiomyopathy	0.000941	0.00377	CcSEcCtD
L-DOPA—Angioedema—Lisinopril—dilated cardiomyopathy	0.00093	0.00373	CcSEcCtD
L-DOPA—Isoprenaline—ADRB1—dilated cardiomyopathy	0.000927	0.0588	CrCbGaD
L-DOPA—Malaise—Lisinopril—dilated cardiomyopathy	0.000918	0.00368	CcSEcCtD
L-DOPA—Syncope—Lisinopril—dilated cardiomyopathy	0.000913	0.00366	CcSEcCtD
L-DOPA—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000912	0.00366	CcSEcCtD
L-DOPA—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000911	0.00366	CcSEcCtD
L-DOPA—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000905	0.00363	CcSEcCtD
L-DOPA—Palpitations—Lisinopril—dilated cardiomyopathy	0.0009	0.00361	CcSEcCtD
L-DOPA—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000895	0.00359	CcSEcCtD
L-DOPA—Cough—Lisinopril—dilated cardiomyopathy	0.000888	0.00356	CcSEcCtD
L-DOPA—Urticaria—Furosemide—dilated cardiomyopathy	0.00088	0.00353	CcSEcCtD
L-DOPA—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000875	0.00351	CcSEcCtD
L-DOPA—SLC7A5—cardiac atrium—dilated cardiomyopathy	0.000871	0.0683	CbGeAlD
L-DOPA—Chest pain—Lisinopril—dilated cardiomyopathy	0.000867	0.00348	CcSEcCtD
L-DOPA—Anxiety—Lisinopril—dilated cardiomyopathy	0.000864	0.00346	CcSEcCtD
L-DOPA—Norepinephrine—ADRB1—dilated cardiomyopathy	0.000859	0.0544	CrCbGaD
L-DOPA—Droxidopa—ADRB2—dilated cardiomyopathy	0.000858	0.0544	CrCbGaD
L-DOPA—Discomfort—Lisinopril—dilated cardiomyopathy	0.000856	0.00343	CcSEcCtD
L-DOPA—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000848	0.0034	CcSEcCtD
L-DOPA—Confusional state—Lisinopril—dilated cardiomyopathy	0.000838	0.00336	CcSEcCtD
L-DOPA—Oedema—Lisinopril—dilated cardiomyopathy	0.000831	0.00333	CcSEcCtD
L-DOPA—Shock—Lisinopril—dilated cardiomyopathy	0.000817	0.00328	CcSEcCtD
L-DOPA—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000816	0.00327	CcSEcCtD
L-DOPA—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000813	0.00326	CcSEcCtD
L-DOPA—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000803	0.00322	CcSEcCtD
L-DOPA—Dopamine—ADRB1—dilated cardiomyopathy	0.000798	0.0506	CrCbGaD
L-DOPA—Asthenia—Furosemide—dilated cardiomyopathy	0.000794	0.00319	CcSEcCtD
L-DOPA—Anorexia—Lisinopril—dilated cardiomyopathy	0.000792	0.00318	CcSEcCtD
L-DOPA—Pruritus—Furosemide—dilated cardiomyopathy	0.000783	0.00314	CcSEcCtD
L-DOPA—Isoprenaline—ADRB2—dilated cardiomyopathy	0.00078	0.0494	CrCbGaD
L-DOPA—Epinephrine—ADRB1—dilated cardiomyopathy	0.000779	0.0494	CrCbGaD
L-DOPA—Hypotension—Lisinopril—dilated cardiomyopathy	0.000776	0.00311	CcSEcCtD
L-DOPA—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000758	0.00304	CcSEcCtD
L-DOPA—Insomnia—Lisinopril—dilated cardiomyopathy	0.000751	0.00301	CcSEcCtD
L-DOPA—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000746	0.00299	CcSEcCtD
L-DOPA—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000741	0.00297	CcSEcCtD
L-DOPA—Epinephrine—TNF—dilated cardiomyopathy	0.000739	0.0468	CrCbGaD
L-DOPA—Somnolence—Lisinopril—dilated cardiomyopathy	0.000739	0.00296	CcSEcCtD
L-DOPA—Dizziness—Furosemide—dilated cardiomyopathy	0.000732	0.00294	CcSEcCtD
L-DOPA—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000731	0.00293	CcSEcCtD
L-DOPA—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000722	0.0029	CcSEcCtD
L-DOPA—Norepinephrine—ADRB2—dilated cardiomyopathy	0.000722	0.0458	CrCbGaD
L-DOPA—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000717	0.00288	CcSEcCtD
L-DOPA—Fatigue—Lisinopril—dilated cardiomyopathy	0.000716	0.00287	CcSEcCtD
L-DOPA—Constipation—Lisinopril—dilated cardiomyopathy	0.00071	0.00285	CcSEcCtD
L-DOPA—Pain—Lisinopril—dilated cardiomyopathy	0.00071	0.00285	CcSEcCtD
L-DOPA—Vomiting—Furosemide—dilated cardiomyopathy	0.000704	0.00282	CcSEcCtD
L-DOPA—Rash—Furosemide—dilated cardiomyopathy	0.000698	0.0028	CcSEcCtD
L-DOPA—Dermatitis—Furosemide—dilated cardiomyopathy	0.000697	0.0028	CcSEcCtD
L-DOPA—Headache—Furosemide—dilated cardiomyopathy	0.000694	0.00278	CcSEcCtD
L-DOPA—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000685	0.00275	CcSEcCtD
L-DOPA—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000679	0.00273	CcSEcCtD
L-DOPA—Urticaria—Lisinopril—dilated cardiomyopathy	0.00066	0.00265	CcSEcCtD
L-DOPA—Nausea—Furosemide—dilated cardiomyopathy	0.000658	0.00264	CcSEcCtD
L-DOPA—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000657	0.00263	CcSEcCtD
L-DOPA—Epinephrine—ADRB2—dilated cardiomyopathy	0.000655	0.0415	CrCbGaD
L-DOPA—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000612	0.00246	CcSEcCtD
L-DOPA—Asthenia—Lisinopril—dilated cardiomyopathy	0.000596	0.00239	CcSEcCtD
L-DOPA—Pruritus—Lisinopril—dilated cardiomyopathy	0.000588	0.00236	CcSEcCtD
L-DOPA—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000568	0.00228	CcSEcCtD
L-DOPA—Dizziness—Lisinopril—dilated cardiomyopathy	0.000549	0.0022	CcSEcCtD
L-DOPA—Vomiting—Lisinopril—dilated cardiomyopathy	0.000528	0.00212	CcSEcCtD
L-DOPA—Rash—Lisinopril—dilated cardiomyopathy	0.000524	0.0021	CcSEcCtD
L-DOPA—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000523	0.0021	CcSEcCtD
L-DOPA—Headache—Lisinopril—dilated cardiomyopathy	0.00052	0.00209	CcSEcCtD
L-DOPA—Nausea—Lisinopril—dilated cardiomyopathy	0.000493	0.00198	CcSEcCtD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000263	0.00216	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—RAC1—dilated cardiomyopathy	0.000263	0.00216	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000262	0.00216	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000254	0.00209	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000254	0.00209	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000254	0.00209	CbGpPWpGaD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000254	0.00209	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000251	0.00206	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000251	0.00206	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.000242	0.00199	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.000242	0.00199	CbGpPWpGaD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000241	0.00198	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000236	0.00195	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000233	0.00192	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000233	0.00191	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000229	0.00188	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000228	0.00188	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000226	0.00186	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000225	0.00185	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000225	0.00185	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000224	0.00184	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000224	0.00184	CbGpPWpGaD
L-DOPA—PSIP1—Disease—RAC1—dilated cardiomyopathy	0.000223	0.00184	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000217	0.00179	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000217	0.00178	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000215	0.00177	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000215	0.00177	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000214	0.00176	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000213	0.00175	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000209	0.00172	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000209	0.00172	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000208	0.00171	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000207	0.0017	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000207	0.0017	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000206	0.0017	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000202	0.00166	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.0002	0.00165	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—RAF1—dilated cardiomyopathy	0.0002	0.00164	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000196	0.00161	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000194	0.00159	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000194	0.00159	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000194	0.00159	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000193	0.00159	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000192	0.00158	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000192	0.00158	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000192	0.00158	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000191	0.00157	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000191	0.00157	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000186	0.00153	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000183	0.00151	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00018	0.00148	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000179	0.00147	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000178	0.00146	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000174	0.00143	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—RAF1—dilated cardiomyopathy	0.000174	0.00143	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000173	0.00142	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000173	0.00142	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000172	0.00142	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000172	0.00142	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000171	0.0014	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000165	0.00136	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000165	0.00136	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000165	0.00136	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000164	0.00135	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000158	0.0013	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000158	0.0013	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000157	0.00129	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000153	0.00126	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000153	0.00126	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000151	0.00124	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.00015	0.00123	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.00015	0.00123	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000149	0.00123	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000148	0.00122	CbGpPWpGaD
L-DOPA—PSIP1—Disease—RAF1—dilated cardiomyopathy	0.000148	0.00122	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000148	0.00121	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000147	0.00121	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000146	0.0012	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000146	0.0012	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000141	0.00116	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00014	0.00115	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000139	0.00115	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000139	0.00114	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000138	0.00113	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000136	0.00112	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000136	0.00112	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000135	0.00111	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000132	0.00108	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000131	0.00108	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000127	0.00104	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000122	0.001	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000122	0.001	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.00012	0.000989	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000116	0.000958	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000115	0.000946	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000113	0.00093	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000112	0.000925	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.00011	0.000908	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.00011	0.000908	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000109	0.000901	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000109	0.0009	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000109	0.0009	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000109	0.000898	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000108	0.000888	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000108	0.000888	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000107	0.000878	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000105	0.000862	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000104	0.000855	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000103	0.000851	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000103	0.000844	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000102	0.000837	CbGpPWpGaD
L-DOPA—PSIP1—Disease—EGFR—dilated cardiomyopathy	0.000102	0.000836	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.0001	0.000826	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.0001	0.000824	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.95e-05	0.000819	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—ADRB1—dilated cardiomyopathy	9.94e-05	0.000818	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	9.94e-05	0.000818	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	9.94e-05	0.000818	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	9.86e-05	0.000811	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL2—dilated cardiomyopathy	9.81e-05	0.000807	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AGTR2—dilated cardiomyopathy	9.81e-05	0.000807	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	9.72e-05	0.0008	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.35e-05	0.000769	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.33e-05	0.000767	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	9.24e-05	0.00076	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCR3—dilated cardiomyopathy	9.12e-05	0.00075	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	8.95e-05	0.000736	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.91e-05	0.000733	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	8.87e-05	0.00073	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.84e-05	0.000727	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.84e-05	0.000727	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—ADRB1—dilated cardiomyopathy	8.83e-05	0.000726	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.49e-05	0.000698	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.47e-05	0.000697	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	8.42e-05	0.000692	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	8.31e-05	0.000683	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GPX1—dilated cardiomyopathy	8.3e-05	0.000683	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	8.26e-05	0.00068	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	8.26e-05	0.00068	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	8.26e-05	0.00068	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCR3—dilated cardiomyopathy	8.22e-05	0.000676	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AGT—dilated cardiomyopathy	8.1e-05	0.000666	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CD36—dilated cardiomyopathy	8.08e-05	0.000665	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.06e-05	0.000663	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	7.99e-05	0.000657	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.96e-05	0.000655	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—AGT—dilated cardiomyopathy	7.91e-05	0.000651	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	7.88e-05	0.000648	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	7.78e-05	0.00064	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	7.77e-05	0.000639	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	7.68e-05	0.000632	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	7.64e-05	0.000629	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AGTR1—dilated cardiomyopathy	7.54e-05	0.00062	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AGTR2—dilated cardiomyopathy	7.51e-05	0.000617	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL2—dilated cardiomyopathy	7.51e-05	0.000617	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	7.44e-05	0.000612	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.35e-05	0.000604	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AGT—dilated cardiomyopathy	7.28e-05	0.000599	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	7.25e-05	0.000596	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—ADRB2—dilated cardiomyopathy	7.15e-05	0.000589	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	7.03e-05	0.000578	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCR3—dilated cardiomyopathy	6.98e-05	0.000574	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.89e-05	0.000566	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.8e-05	0.000559	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.76e-05	0.000556	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.61e-05	0.000544	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.58e-05	0.000541	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.53e-05	0.000537	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.52e-05	0.000537	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.52e-05	0.000537	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.45e-05	0.00053	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	6.36e-05	0.000523	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.25e-05	0.000514	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.2e-05	0.00051	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.12e-05	0.000503	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.06e-05	0.000499	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	6.03e-05	0.000496	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AGT—dilated cardiomyopathy	5.97e-05	0.000491	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AGT—dilated cardiomyopathy	5.92e-05	0.000487	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.87e-05	0.000483	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.87e-05	0.000483	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.87e-05	0.000483	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AGT—dilated cardiomyopathy	5.84e-05	0.000481	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.79e-05	0.000477	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.79e-05	0.000477	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	5.77e-05	0.000475	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.63e-05	0.000463	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.62e-05	0.000462	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.55e-05	0.000457	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.54e-05	0.000456	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—ADRB2—dilated cardiomyopathy	5.47e-05	0.00045	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.46e-05	0.000449	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.39e-05	0.000443	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AGT—dilated cardiomyopathy	5.38e-05	0.000442	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AGT—dilated cardiomyopathy	5.31e-05	0.000437	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.29e-05	0.000435	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.22e-05	0.000429	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.02e-05	0.000413	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RAC1—dilated cardiomyopathy	5.01e-05	0.000412	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.99e-05	0.000411	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AGT—dilated cardiomyopathy	4.78e-05	0.000393	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.76e-05	0.000391	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.68e-05	0.000385	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.52e-05	0.000371	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.47e-05	0.000368	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.46e-05	0.000366	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.43e-05	0.000365	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.43e-05	0.000365	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.28e-05	0.000352	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.25e-05	0.00035	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.23e-05	0.000348	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.15e-05	0.000341	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.12e-05	0.000339	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.09e-05	0.000336	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AGT—dilated cardiomyopathy	4.06e-05	0.000334	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.99e-05	0.000328	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.85e-05	0.000317	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.73e-05	0.000307	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RAC1—dilated cardiomyopathy	3.69e-05	0.000304	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.68e-05	0.000303	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.68e-05	0.000303	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.63e-05	0.000299	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AGT—dilated cardiomyopathy	3.53e-05	0.00029	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.41e-05	0.00028	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RAC1—dilated cardiomyopathy	3.33e-05	0.000274	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RAF1—dilated cardiomyopathy	3.32e-05	0.000273	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RAC1—dilated cardiomyopathy	3.28e-05	0.00027	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.23e-05	0.000266	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AGT—dilated cardiomyopathy	3.18e-05	0.000261	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AGT—dilated cardiomyopathy	3.14e-05	0.000258	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.84e-05	0.000234	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.82e-05	0.000232	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.78e-05	0.000229	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.56e-05	0.000211	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.53e-05	0.000208	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RAC1—dilated cardiomyopathy	2.51e-05	0.000207	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RAF1—dilated cardiomyopathy	2.45e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AGT—dilated cardiomyopathy	2.4e-05	0.000197	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—dilated cardiomyopathy	2.28e-05	0.000187	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.21e-05	0.000181	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RAF1—dilated cardiomyopathy	2.18e-05	0.000179	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.93e-05	0.000159	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	1.91e-05	0.000157	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	1.86e-05	0.000153	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—dilated cardiomyopathy	1.68e-05	0.000138	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	1.67e-05	0.000138	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RAF1—dilated cardiomyopathy	1.66e-05	0.000137	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.51e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—dilated cardiomyopathy	1.49e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—dilated cardiomyopathy	1.14e-05	9.39e-05	CbGpPWpGaD
